Ipamorelin: A Gentle Nudge to the Body's Own Growth-Hormone Switch

The short version

Ipamorelin is a small, lab-made peptide — five amino acids long — designed to flip a specific hormonal switch in the pituitary gland, the pea-sized organ at the base of the brain that controls growth hormone release. That switch is called the ghrelin receptor, the same one that responds to the "hunger hormone" ghrelin. Flipping it causes a short burst of the body's own growth hormone, rather than adding growth hormone directly.

What made Ipamorelin notable when it was developed is that it does this cleanly: unlike earlier compounds in its family, it does not meaningfully raise stress hormones like cortisol at the same time. That said, Ipamorelin has never been approved as a medicine anywhere, its one real human clinical trial did not prove it worked for its tested use, and there is no long-term human safety data. It is sold only as a research chemical, and nothing here recommends using it.

What it is

Ipamorelin's chemical name describes its structure: Aib-His-D-2-Nal-D-Phe-Lys-NH2, a five-amino-acid (pentapeptide) chain. It was derived from an older compound, GHRP-1, by removing a middle two-amino-acid segment. Two of its building blocks — D-2-naphthylalanine and D-phenylalanine — are mirror-image ("D-form") versions of natural amino acids, which makes the molecule far more resistant to being broken down by the body's enzymes than a natural peptide would be. This is a common trick in peptide design: swap in a D-amino acid, and a compound that would otherwise last minutes can last hours.

Ipamorelin acts on the ghrelin receptor, more formally called the growth hormone secretagogue receptor (GHS-R1a). "Secretagogue" simply means something that triggers a gland to release a substance — in this case, growth hormone from the pituitary.

How it works

The pituitary gland contains cells called somatotrophs whose entire job is to store and release growth hormone. Ipamorelin binds to the ghrelin receptor on those cells and triggers them to release a pulse of growth hormone into the bloodstream — the same basic signal the body uses on its own, just switched on from the outside. Because it uses a different receptor and pathway than growth-hormone-releasing hormone (GHRH), it is often studied alongside GHRH-type compounds like CJC-1295, on the idea that combining two different growth-hormone triggers might produce a bigger combined pulse than either alone — though that specific combination has not been tested directly in a trial.

Ipamorelin's defining feature, established in its earliest lab characterization, is that it does this fairly selectively: even at high doses, it does not meaningfully raise cortisol, ACTH, or prolactin the way earlier ghrelin-receptor compounds like GHRP-6 and GHRP-2 did. That selectivity is the main reason Ipamorelin displaced those older compounds in research use, though it does not mean the compound is free of other effects — the same ghrelin receptor also sits on cells involved in appetite and gut motility, and on insulin-releasing cells in the pancreas.

What the research shows

Most recent finding. A 2024 study in ferrets found that Ipamorelin reduced the body-weight loss caused by the chemotherapy drug cisplatin by about 24% during the delayed phase of the reaction, but — unlike a related compound tested in the same study — it did not reduce nausea or vomiting ^[1]. This is the newest published data point on Ipamorelin in any species.

The one human clinical trial. In a Phase 2 trial of 114 adults recovering from bowel surgery, Ipamorelin given intravenously twice a day for up to a week did not significantly speed up the return of bowel function compared with placebo (25.3 hours versus 32.6 hours to first tolerated meal — a difference that did not reach statistical significance) ^[3]. This remains the only controlled human trial of Ipamorelin ever published, and its primary goal was not met.

Human pharmacokinetics. A separate study in eight healthy men measured how Ipamorelin moves through the body: a roughly two-hour half-life, with the growth-hormone pulse peaking about 40 minutes after dosing ^[4].

Animal safety signal. A 28-day study of a related ghrelin-receptor compound (not Ipamorelin itself) found dose-dependent heart-muscle damage in rats ^[2] — a class-level warning sign, not a finding about Ipamorelin specifically, but one reason chronic dosing of any compound in this family deserves caution.

Bone growth in rats. Two weeks of Ipamorelin dosing increased the rate of long-bone growth in adult female rats, without changing overall IGF-1 levels in the blood — suggesting at least part of the effect happens locally rather than through the whole-body hormone axis ^[5].

Reported effects, cautions & safety

The patterns below are anecdotal, not clinical evidence — they come from public posts in research-use and peptide-community forums, not from controlled studies, and none of them come with a verified dose or source.

Reported benefits: The most consistently mentioned effect is deeper, more restorative sleep, often showing up within the first one to two weeks, sometimes alongside unusually vivid dreams early on that settle down over time. People also frequently describe faster recovery and less soreness after exercise, and some report a gradual shift toward a leaner body composition over several months.

Reported adverse effects: A warm flush across the face or chest shortly after injection — often compared to a niacin flush — comes up often, along with occasional tingling in the hands or feet, mild puffiness or water retention, and a noticeable uptick in hunger in the hours after dosing. Some people describe feeling briefly dizzy or "spacey" after injecting, especially early on, and mild redness or irritation at the injection site is common. A number of posters note that the effects, especially on sleep, seem to fade after three or four months of continuous use.

Cited cautions:

• Active or recent cancer: Growth hormone raises IGF-1, a hormone well known to help cells grow and divide — which is exactly why a current or recent history of cancer is treated as a reason to avoid growth-hormone-boosting compounds generally. This is a mechanism-based caution, not something tested directly in an Ipamorelin trial.
• Diabetes or insulin resistance: Growth hormone can reduce the body's sensitivity to insulin, and Ipamorelin's target receptor also sits on insulin-releasing pancreatic cells — so its net effect on blood sugar in someone with existing glucose problems is genuinely unclear.
• Heart conditions: A related ghrelin-receptor compound caused heart-muscle damage in rats after a month of dosing ^[2] — a signal that makes long-term use of any compound in this family a reasonable concern for anyone with existing heart disease.
• Weight or appetite-sensitive conditions: Because the ghrelin receptor also drives hunger, some increase in appetite and fat storage is a plausible class-level effect, separate from any growth-hormone effect.
• Unverified long-term safety: The only controlled human data are the one inconclusive surgical-recovery trial and one short pharmacokinetic study ^[3][4] — there is no long-term human safety record, and research-grade material is not subject to pharmaceutical quality control.

Where it fits in Research Peptide Fundamentals

Ipamorelin sits at the least-regulated end of this guide's four compounds — a research chemical with animal data, one inconclusive human trial, and no approval anywhere. That is a useful contrast to NAD+, which occupies a supplement middle-ground, and to Semaglutide and Tesamorelin, both of which cleared full human trial programs and became approved medicines. Reading Ipamorelin alongside the other three is a fast way to understand just how differently "research peptide" gets used depending on the compound. See the comparison page for all four side by side.